One of the greatest forces in wealth-building is the power of compounding. That is why every portfolio needs some set-it-and-forget-it stocks. When you find a good compounder, you should hold it forever.It is well known that investors do poorly timing the market. Due to the psychological nature of investing, most investors tend to buy at the top and sell at the bottom. As a result, they end up underperforming the market indices.Similarly, trying to time the tops and bottoms in the best-in-class compounders ...

While innovations such as artificial intelligence have become all the rage, there’s another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven’t considered the sector, it’s really time to focus on biotech stocks.First, let’s get the obvious matter out of the way: biotech stocks benefit broadly from a permanently relevant narrative. That doesn’t mean individual companies are guaranteed to rise. It’s just that the concept of addressing diseases an ...

AstraZeneca (AZN) announced positive results from the phase III NIAGARA study, which evaluated Imfinzi in patients with muscle-invasive bladder cancer (MIBC).Study participants who were enrolled in the NIAGARA study were randomized to receive Imfinzi plus chemotherapy or chemotherapy alone before cystectomy (bladder removal surgery), followed by Imfinzi or no further treatment after surgery.The study achieved statistically significant and clinically meaningful improvement in its primary endpoint of event-fr ...

There are multiple reasons to consider exposure to pharmaceutical stocks for the long-term portfolio. First, pharma stocks have a low-beta and provide and help in reducing the overall beta of a portfolio that’s overweight growth stocks. Further, pharma stock represents a business that’s relatively immune to economic shocks.At the same time, well established pharma companies have healthy cash flows and therefore sustained value creation through dividends. With these factors in consideration, investors should ...

You won't need much money to start investing in these great stocks.A low price doesn't necessarily mean low quality. That's true with lots of products and services. And it's true with stocks, too.We asked Three Motley Fool contributors to name no-brainer healthcare stocks to buy for under $100 right now. Here's why they picked AstraZeneca (AZN 0.41%), Bristol Myers Squibb (BMY 2.17%), and Pfizer (PFE).AstraZeneca is a growth beast with loads of potential upsideDavid Jagielski (AstraZeneca): Shares of AstraZ ...

AstraZeneca (AZN) announced that the European Commission (EC) has approved Truqap (capivasertib) in combination with Faslodex (fulvestrant) for a breast cancer indication.The EC has approved Truqap in combination with Faslodex for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors have qualifying alterations in the PIK3CA, AKT1 or PTEN genes following recurrence or progression on or after an endocrine-based regimen.Following ...

PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The National Cancer Institute's (NCI) funding of research projects is predicted to empower the Pancreatic Cancer Market to grow. A report from Future Market Insights said that: "… the increasing adoption of therapeutic strategies is catapulting the pancreatic cancer market forward. Unlike traditional therapeutic methods such as chemotherapy, targeted therapy isolates receptor sites in cancer cells while causing no harm to t ...

公司动态 - AstraZeneca宣布其新批准的乳腺癌药物Truqap（capivasertib）在治疗晚期或转移性三阴性乳腺癌（TNBC）的III期研究CAPItello-290中未能达到其双重主要终点[1] - CAPItello-290研究评估了Truqap与化疗药物紫杉醇（paclitaxel）联合使用与安慰剂联合紫杉醇在一线治疗局部晚期（不可手术）或转移性TNBC患者中的安全性和有效性[2] - 研究显示，Truqap加紫杉醇的组合在总体生存率方面未能优于安慰剂加紫杉醇，无论是在总体研究人群还是在具有特定生物标志物改变（PIK3CA, AKT1或PTEN）的亚组患者中[3] 产品信息 - Truqap已在美国基于CAPItello-291 III期研究数据，于2023年11月获批用于治疗HR阳性、HER2阴性的局部晚期或转移性乳腺癌[4] - 欧洲药品管理局的人用药品委员会在2024年4月给出了积极意见，推荐批准Truqap与Faslodex联合使用，治疗晚期ER阳性乳腺癌[5] - Truqap还在进行其他晚期研究，用于治疗乳腺癌以及与其他疗法联合治疗前列腺癌[6] - Truqap在2024年第一季度产生了5000万美元的销售额，2023年第四季度为600万美元[6] 市场表现 - AstraZeneca的股价今年迄今已上涨17.7%，而行业整体上涨了20.2%[4] - 肿瘤学销售占AstraZeneca总收入的约40%，并在2023年增长了21%[7] 其他公司信息 - AstraZeneca正在通过现有产品的标签扩展和推进肿瘤学管线候选产品来加强其肿瘤学产品组合[7]

文章核心观点 - 公司股价在最新交易中下跌0.35%,低于标普500指数0.77%的涨幅 [1] - 公司股价在过去一个月内上涨3.5%,超过医疗行业1.49%的涨幅,但低于标普500指数3.71%的涨幅 [2] - 公司即将公布的季度财报中,每股收益预计下降9.26%,但营收预计增长9.4% [3] - 全年来看,公司每股收益和营收分别预计增长11.29%和13.03% [4] - 分析师对公司业绩和盈利能力持乐观态度,体现在对公司预测数据的上调 [5][6][7] - 公司当前市盈率为19.72倍,高于行业平均水平14.54倍 [8][9] - 公司所在的大型制药行业目前在250多个行业中排名靠后,位于底部41% [10][11]

文章核心观点 - FDA批准AstraZeneca的癌症药物Imfinzi联合化疗用于治疗失配修复缺陷(dMMR)晚期或复发子宫内膜癌 [1][2][3] - Imfinzi联合化疗较单独化疗可将疾病进展或死亡风险降低58% [3] - Imfinzi联合化疗的安全性良好,未发现新的安全问题 [4] - DUO-E研究还在评估Imfinzi联合Lynparza维持治疗的疗效,该方案也已达到无进展生存期主要终点 [5] - Imfinzi是AstraZeneca重要的肿瘤业务收入驱动器,第一季度销售额同比增长33% [9][10] 公司相关 - AstraZeneca目前评级为持有评级 [11] - Imfinzi已获批用于多种适应症,包括非小细胞肺癌、小细胞肺癌、胆道癌和肝细胞癌等 [7] - Imfinzi正在多个适应症进行III期临床试验,包括早期非小细胞肺癌和小细胞肺癌、早期胃癌和肝癌等 [8] 行业相关 - 同行业公司Acrivon Therapeutics、Aligos Therapeutics和RAPT Therapeutics评级为买入 [12][15][16] - 这些公司近期业绩表现良好,盈利预测也有所改善 [13][14][16][17][18]